Clinical Meetings - Formulary

ADVERTISEMENT

Clinical Meetings

Statins found beneficial in wider range of patients, major study finds

January 1, 2002

Anaheim, CA-The largest trial of cholesterol-lowering therapy ever conducted extends the current indications for statin therapy, reported Rory Collins, MD.

For first time, an antianginal agent shown to improve clinical outcomes

January 1, 2002

An agent developed specifically for the treatment of angina reduces the incidence of major coronary events, reported Henry Dargie, MD, who presented the results of a trial known as the Impact of Nicorandil in Angina (IONA). It is believed to be the first large-scale trial to report on the effects of a specific antianginal drug on clinical outcome.

Ranolazine enhances exercise performance when added to standard medications

January 1, 2002

Ranolazine, the first in a new class of antianginal agents called the partial fatty acid oxidation (pFOX) inhibitors, improves exercise performance and reduces angina frequency in patients who still have symptoms despite treatment with other antianginal medications, according to Bernard Chaitman, MD. He reported the results of a Phase III study called the Combination Assessment of Ranolazine in Stable Angina (CARISA).

American Urological Association: Overactive bladder agent demonstrates efficacy, tolerability in phase 3 trial

July 1, 2011

The selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolderated, according to results of a phase 3 study.

American Urological Association: 5-ARI, alpha-blocker differ in number of BPH-related complications

July 1, 2011

The 5-alpha-reductase inhibitor dutasteride is associated with markedly lower BPH-related complication rates than the alpha-blocker tamsulosin, according to analysis of 2 large trials.

Academy of Managed Care Pharmacy: CER reviews valuable, but not used to full potential

July 1, 2011

Comparative effectiveness research reviews are valuable resources for guiding medication use decisions, but they are underutilized, according to a recent presentation.

Academy of Managed Care Pharmacy: Generic drug trend forecasting can help MCOs rein in costs

July 1, 2011

Some of the most prescribed blockbuster medications will lose market exclusivity in the next couple of years, according to a recent presentation.

Academy of Managed Care Pharmacy: Cancer, diabetes, cardiovascular agents fill pipeline

June 1, 2011

The pipeline continues to decline from 4 to 5 years ago where smaller molecules led the way, according to a current state of the pharmaceutical pipeline presentation at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase in Minneapolis.

Academy of Managed Care Pharmacy: Specialty drug approvals trend upward; biobetters gain momentum

June 1, 2011

Within the next 5 years, approximately $100 billion will be lost on previous blockbuster brands that will lose patent protection.

ADVERTISEMENT

Formulary Issue
Stay connected to Formulary
Receive web-exclusive articles, clinical news, and conference updates!

ADVERTISEMENT

Modern Medicine logoFormulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.

ADVERTISEMENT

Click here